, licensed from Pfizer</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">SGLT2 inhibitor</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Type 2 diabetes</td></tr><tr><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Fasiglifam (TAK-875)</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Takeda</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">G-protein-coupled receptor (GPCR) 40 agonist</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Type 2 diabetes</td></tr><tr><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">FIAsp (NN1218)</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Novo Nordisk</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Faster-acting formulation of insulin aspart</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Type 1 and 2 diabetes</td></tr><tr><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Forxiga  (dapagliflozin)</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Bristol Myers Squibb and AstraZeneca</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">SGLT2 inhibitor</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Once-daily tablets for adults with type 2 diabetes</td></tr><tr><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">IDegLira (NN9068)</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Novo Nordisk</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Combination drug therapy</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Type 2 diabetes</td></tr><tr><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Invokana (canagliflozin)</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Johnson &amp; Johnson</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">SGLT2 inhibitor</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Once-daily tablets for adults with type 2 diabetes</td></tr><tr><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Ipragliflozin L-proline (ASP1941)</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Astellas, MSD, and Kotobuki Pharmaceutical</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">SGLT2 inhibitor</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Type 2 diabetes</td></tr><tr><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Luseogliflozin hydrate (TS-071)</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Taisho Pharmaceutical</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">SGLT2 inhibitor</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Once-daily for type 2 diabetes</td></tr><tr><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">LixiLan (lixisenatide+ insulin glargine)</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Sanofi; lixisenatide</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Combination drug therapy </td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Type 2 diabetes</td></tr><tr><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Lyxumia<sup> </sup> (lixisenatide)</td><td align=\"center\" valign=\"middle\" style=\"border-bottom:solid thin\" rowspan=\"1\" colspan=\"1\">Sanofi; licensed from Zealand Pharma</td><td align=\"center\" valign=\"middle\" style=\"border-bottom: